Consistently, we discovered that the anti-obesity effect of PEGyAMPH is abrogated by selective ADRB2 antagonism (BUT, Figures 7H and 7I), further validating the importance of this pathway for PEGyAMPH’s metabolic effects. This evidence concerns the gene ADRB2 and Obesity.